The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models

References

• Sung H, Ferlay J, Siegel RL., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–451. doi:10.3322/caac.21583
   PubMed Web of Science ®Google Scholar
• Osborne CK, Wood AJJ. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609–1618. doi:10.1056/NEJM199811263392207
   PubMed Web of Science ®Google Scholar
• Boér K. Fulvestrant in advanced breast cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2017;9(7):465–479. doi:10.1177/1758834017711097
   PubMed Web of Science ®Google Scholar
• Piezzo M, Cocco S, Caputo R, et al. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. Int J Mol Sci. 2020;22(1):21. doi:10.3390/ijms22010021
   PubMedGoogle Scholar
• Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1(3):222–231. doi:10.1038/35106065
   PubMed Web of Science ®Google Scholar
• de Dueñas EM, Gavila-Gregori J, Olmos-Antón S, et al. Preclinical and clinical development of palbociclib and future perspectives. Clin Transl Oncol. 2018;20(9):1136–1144. doi:10.1007/s12094-018-1850-3
   PubMed Web of Science ®Google Scholar
• Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol. 1995;15(5):2672–2681. doi:10.1128/MCB.15.5.2672
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Cancer cell cycles. Science. 1996;274(5293):1672–1677. doi:10.1126/science.274.5293.1672
   PubMed Web of Science ®Google Scholar
• Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 1997;13(1):261–291. doi:10.1146/annurev.cellbio.13.1.261
   PubMedGoogle Scholar
• Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998;18(2):753–761. doi:10.1128/MCB.18.2.753
   PubMed Web of Science ®Google Scholar
• Scott SC, Lee SS, Abraham J. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer. Semin Oncol. 2017;44(6):385–394. doi:10.1053/j.seminoncol.2018.01.006
   PubMed Web of Science ®Google Scholar
• Piezzo M, Chiodini P, Riemma M, et al. Progression-free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis. Int J Mol Sci. 2020;21(22):1.
   Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. doi:10.1056/NEJMoa1607303
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209–219. doi:10.1056/NEJMoa1505270
   PubMed Web of Science ®Google Scholar
• Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817–827. doi:10.1016/S0140-6736(20)30165-3
   PubMed Web of Science ®Google Scholar
• Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2021;81(3):317–331. doi:10.1007/s40265-020-01461-2
   PubMed Web of Science ®Google Scholar
• Sledge GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884. doi:10.1200/JCO.2017.73.7585
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987–3998. doi:10.1200/JCO.20.02514
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646. doi:10.1200/JCO.2017.75.6155
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748. doi:10.1056/NEJMoa1609709
   PubMed Web of Science ®Google Scholar
• Xu ZB, Hu LH, Liu YC, et al. Preclinical evaluation of TQB3616, a highly potent and selective small-molecule CDK4/6 inhibitor. Cancer Res. 2018;78:2.
   Google Scholar
• van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol. 2011;731:237–245.
   PubMedGoogle Scholar
• Aapro MS, Eliason JF, Krauer F, Alberto P. Colony formation in vitro as a prognostic indicator for primary breast cancer. J Clin Oncol. 1987;5(6):890–896. doi:10.1200/JCO.1987.5.6.890
   PubMed Web of Science ®Google Scholar
• Nunez R. DNA measurement and cell cycle analysis by flow cytometry. Curr Issues Mol Biol. 2001;3(3):67–70.
   PubMedGoogle Scholar
• Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006;1(3):1458–1461. doi:10.1038/nprot.2006.238
   PubMed Web of Science ®Google Scholar
• Crowley LC, Scott AP, Marfell BJ, Boughaba JA, Chojnowski G, Waterhouse NJ. Measuring cell death by propidium iodide uptake and flow cytometry. Cold Spring Harb Protoc. 2016;2016:1.
   Google Scholar
• Novikoff AB. Electron microscopy: cytology of cell fractions. Science. 1956;124(3229):969–972. doi:10.1126/science.124.3229.969
   PubMed Web of Science ®Google Scholar
• Hino H, Iriyama N, Kokuba H, et al. Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes. Cancer Sci. 2020;111(6):2132–2145. doi:10.1111/cas.14419
   PubMed Web of Science ®Google Scholar
• Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res. 2014;20(13):3379–3383. doi:10.1158/1078-0432.CCR-13-1551
   PubMed Web of Science ®Google Scholar
• Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 2002;1602(1):73–87. doi:10.1016/s0304-419x(02)00037-9
   PubMed Web of Science ®Google Scholar
• Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G 1 checkpoint. Mol Cell Biol. 1996;16(12):6917–6925. doi:10.1128/MCB.16.12.6917
   PubMed Web of Science ®Google Scholar
• Shao J, Sheng H, DuBois RN, Beauchamp RD. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J Biol Chem. 2000;275(30):22916–22924. doi:10.1074/jbc.M002235200
   PubMed Web of Science ®Google Scholar
• Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32(5):825–837. doi:10.1007/s10637-014-0120-7
   PubMed Web of Science ®Google Scholar
• Long F, He Y, Fu H, et al. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models. Cancer Sci. 2019;110(4):1420–1430. doi:10.1111/cas.13957
   PubMed Web of Science ®Google Scholar
• Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011;104(12):1862–1868. doi:10.1038/bjc.2011.177
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;8(2):568–576. doi:10.1158/1078-0432.CCR-11-0509
   Google Scholar
• Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016;6(7):740–753. doi:10.1158/2159-8290.CD-16-0095
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.
   PubMed Web of Science ®Google Scholar
• Wonsey DR, Follettie MT. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res. 2005;65(12):5181–5189. doi:10.1158/0008-5472.CAN-04-4059
   PubMed Web of Science ®Google Scholar
• Bergamaschi A, Madak-Erdogan Z, Kim YJ, Choi YL, Lu H, Katzenellenbogen BS. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells. Breast Cancer Res. 2014;16(5):436. doi:10.1186/s13058-014-0436-4
   PubMed Web of Science ®Google Scholar